Innovent ga-arụkọ ọrụ na NeoCura na China iji nyochaa nchekwa, pharmacokinetics, pharmacodynamics na mbido mbụ nke ọgwụgwọ ngwakọta na-eji sintilimab sitere na Innovent na NEO_PLIN2101 sitere na NeoCura na ndị ọrịa kansa, iji kwalite mmepe ụlọ ọgwụ nke ngwakọta immunotherapy maka ọtụtụ etuto siri ike wee kwadebere inyefe ya. ngwa nyocha Ọhụrụ Drug (IND) na National Medical Products Administration (NMPA) n'ọdịnihu dị nso.
Dr. Liu Yongjun, Onye isi oche Innovent, kwuru, sị: "Anyị nwere mmasị na pipeline R&D dị iche iche nke NeoCura na ndị otu nyocha mba ụwa, na anyị nwere obi ụtọ ịbanye na nkwekọrịta usoro a iji nyochaa uru ahụike nke sintilimab yana ọgwụ mgbochi neoantigen maka etuto siri ike. . Innovent nwere pipeline siri ike nwere ikike siri ike na ọgwụ mgbochi ọrịa na usoro ihe ọmụmụ ọrịa kansa. Ugbu a, anyị nwere ọgwụ ọhụrụ akwadoro ma malite na China ma ga-enwe ihe karịrị ọgwụ 10 ọhụrụ ka ewepụtara n'ime afọ 2-3 na-esote. Usoro ikpo okwu anyị jikọtara ọnụ achịkọtala R&D siri ike, mmepe ụlọ ọgwụ na ikike ịzụ ahịa yana dịkwa mma maka ndị mmekọ n'ụlọ na mba ọzọ. Anyị na-atụkwa anya ịga n'ihu ịchọpụta ohere ọhụrụ na ịgbasa ihe ngosi na ịkwalite nrụpụta ọgwụgwọ nke sintilimab yana mgbakwunye na usoro ọgwụgwọ ọhụrụ. Anyị na-atụ anya nkwado zuru oke na nke miri emi n'etiti akụkụ abụọ ahụ n'ọdịnihu. "
Dr. Wang Yi, onye guzobere NeoCura, kwuru, sị: “Ka ọ dị ugbu a, ọgwụ mgbochi neoantigen bụ usoro ọgwụgwọ na-apụta na-agbanwe agbanwe n'ụwa niile. NeoCura nọ na-elekwasị anya na R&D nke ọgwụ mgbochi neoantigen tumor kemgbe e guzobere ya, na-atụ anya imeri ihe ịma aka nke immunotherapy dị ugbu a na ọgwụgwọ etuto siri ike site na itinye teknụzụ ọhụrụ. Mmekọrịta ya na Innovent ga-arụ ọrụ synergistic nke ọgwụ mgbochi neoantigen ahaziri onwe ya na ọgwụ mgbochi monoclonal na ijikọ ọnụ nyochaa mmetụta ụlọ ọgwụ nke ọgwụgwọ ngwakọta na ọgwụgwọ nke etuto siri ike, nke a na-atụ anya na ọ ga-eme ka ọnụọgụ nzaghachi ebumnobi nke immunotherapy nke ọrịa cancer na-ebute ma weta ohere ọhụrụ. maka usoro ọgwụgwọ ọrịa cancer. "
IHE Ị GA-Ewepụ na edemede a:
- Innovent ga-arụkọ ọrụ na NeoCura na China iji nyochaa nchekwa, pharmacokinetics, pharmacodynamics na mbido mbụ nke ọgwụgwọ ngwakọta na-eji sintilimab sitere na Innovent na NEO_PLIN2101 sitere na NeoCura na ndị ọrịa kansa, iji kwalite mmepe ụlọ ọgwụ nke ngwakọta immunotherapy maka ọtụtụ etuto siri ike wee kwadebere inyefe ya. ngwa nyocha Ọhụrụ Drug (IND) na National Medical Products Administration (NMPA) n'ọdịnihu dị nso.
- Mmekọrịta ya na Innovent ga-arụ ọrụ synergistic nke ọgwụ mgbochi neoantigen ahaziri onwe ya na ọgwụ mgbochi monoclonal na ijikọ ọnụ nyochaa mmetụta ụlọ ọgwụ nke ọgwụgwọ ngwakọta na ọgwụgwọ nke etuto siri ike, nke a na-atụ anya na ọ ga-eme ka ọnụọgụ nzaghachi ebumnobi nke immunotherapy nke ọrịa cancer na-ebute ma weta ohere ọhụrụ. maka usoro nchikota cancer.
- NeoCura nọ na-elekwasị anya na R&D nke ọgwụ mgbochi neoantigen tumor kemgbe e guzobere ya, na-atụ anya imeri ihe ịma aka nke immunotherapy dị ugbu a na ọgwụgwọ etuto siri ike site na itinye teknụzụ ọhụrụ.
